Latest stories on OSTX
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight
PR Newswire63 · neutralgeneral
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
StockTitan63 · neutralproduct/pr
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies GAAP EPS of -$0.20 misses by $0.03
Seeking Alpha34 · bearishearnings
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Business Insider50 · neutralgeneral
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies Settles Leonite Debt, Issues Bridge Financing
TipRanks56 · neutralgeneral
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies Ends At-The-Market Equity Sales Program
TipRanks48 · neutralgeneral
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program | OSTX Stock News
StockTitan67 · bullishproduct/pr
8-K/A - OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies Third Quarter 2026 Corporate Outlook | OSTX Stock News
StockTitan56 · neutralgeneral
OS Therapies Secures Convertible Note Financing for Expansion
TipRanks28 · bearishgeneral
OS Therapies Inc (OSTX) files 8-K
SEC 8-K50 · neutralgeneral
OS Therapies Appoints Dr. Craig Eagle to Board of Directors | OSTX Stock News
StockTitan56 · neutralgeneral
OS Therapies Provides U.S. Regulatory Update | OSTX Stock News
StockTitan63 · neutralgeneral
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World | OSTX Stock News
StockTitan63 · neutralproduct/pr